{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:54:30Z","timestamp":1785887670404,"version":"3.56.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22H00440"],"award-info":[{"award-number":["22H00440"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H01016"],"award-info":[{"award-number":["19H01016"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H01016"],"award-info":[{"award-number":["19H01016"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22H00440"],"award-info":[{"award-number":["22H00440"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TMDU priority research areas grant"},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18am0301003h0005"],"award-info":[{"award-number":["18am0301003h0005"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20am0401006h0002"],"award-info":[{"award-number":["20am0401006h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-66765-x","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:01:58Z","timestamp":1766397718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Morpholino\u2013RNA duplex exhibits robust, sustained, and safe steric-block antisense activity by intracerebroventricular and intrathecal injection"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4694-6227","authenticated-orcid":false,"given":"Mitsugu","family":"Yanagidaira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4111-2693","authenticated-orcid":false,"given":"Tetsuya","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7799-4216","authenticated-orcid":false,"given":"Juri","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoe","family":"Ebihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Nawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"66765_CR1","doi-asserted-by":"crossref","unstructured":"Ers\u00f6z, E. & Demir-Dora, D. Unveiling the potential of antisense oligonucleotides: mechanisms, therapies, and safety insights. Drug Dev. Res. 85, e22187 (2024).","DOI":"10.1002\/ddr.22187"},{"key":"66765_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","volume":"20","author":"ST Crooke","year":"2021","unstructured":"Crooke, S. T., Baker, B. F., Crooke, R. M. & Liang, X. hai Antisense technology: an overview and prospectus. Nat. Rev. Drug Discov. 20, 427\u2013453 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"66765_CR3","doi-asserted-by":"publisher","unstructured":"Hill, A. C. & Hall, J. The MOE modification of RNA: origins and widescale impact on the oligonucleotide therapeutics field. Helv. Chim. Acta. 106, https:\/\/doi.org\/10.1002\/hlca.202200169 (2023).","DOI":"10.1002\/hlca.202200169"},{"key":"66765_CR4","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","volume":"40","author":"KM Brown","year":"2022","unstructured":"Brown, K. M. et al. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates. Nat. Biotechnol. 40, 1500\u20131508 (2022).","journal-title":"Nat. Biotechnol."},{"key":"66765_CR5","doi-asserted-by":"publisher","unstructured":"Shah, S. et al. Antisense oligonucleotide rescue of CGG expansion\u2013dependent FMR1 mis-splicing in fragile X syndrome restores FMRP. Proc. Natl. Acad. Sci. USA 120, https:\/\/doi.org\/10.1073\/pnas (2023).","DOI":"10.1073\/pnas"},{"key":"66765_CR6","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N. Engl. J. Med. 381, 1644\u20131652 (2019).","journal-title":"N. Engl. J. Med."},{"key":"66765_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2021.147743","volume":"1775","author":"ER Wengert","year":"2022","unstructured":"Wengert, E. R. et al. Targeted Augmentation of Nuclear Gene Output (TANGO) of Scn1a rescues parvalbumin interneuron excitability and reduces seizures in a mouse model of Dravet Syndrome. Brain Res. 1775, 147743 (2022).","journal-title":"Brain Res."},{"key":"66765_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts, T. C., Langer, R. & Wood, M. J. A. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov. 19, 673\u2013694 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"66765_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/jimd.12251","volume":"44","author":"EC Kuijper","year":"2021","unstructured":"Kuijper, E. C., Bergsma, A. J., Pijnappel, W. W. M. P. & Aartsma-Rus, A. Opportunities and challenges for antisense oligonucleotide therapies. J. Inherit. Metab. Dis. 44, 72\u201387 (2021).","journal-title":"J. Inherit. Metab. Dis."},{"key":"66765_CR10","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/nar\/gkad067","volume":"51","author":"M Egli","year":"2023","unstructured":"Egli, M. & Manoharan, M. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res. 51, 2529\u20132573 (2023).","journal-title":"Nucleic Acids Res."},{"key":"66765_CR11","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1007\/s00415-021-10569-8","volume":"268","author":"B Stolte","year":"2021","unstructured":"Stolte, B. et al. Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters. J. Neurol. 268, 4667\u20134679 (2021).","journal-title":"J. Neurol."},{"key":"66765_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson, M. D. et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 22\u201331 (2018).","journal-title":"N. Engl. J. Med."},{"key":"66765_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/nat.2022.0061","volume":"33","author":"A Goyenvalle","year":"2023","unstructured":"Goyenvalle, A. et al. Considerations in the preclinical assessment of the safety of antisense oligonucleotides. Nucleic Acid Ther. 33, 1\u201316 (2023).","journal-title":"Nucleic Acid Ther."},{"key":"66765_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3233\/JND-221656","volume":"10","author":"PR Clemens","year":"2023","unstructured":"Clemens, P. R. et al. Efficacy and safety of viltolarsen in boys with Duchenne muscular dystrophy: results from the phase 2, open-label, 4-year extension study. J. Neuromuscul. Dis. 10, 439\u2013447 (2023).","journal-title":"J. Neuromuscul. Dis."},{"key":"66765_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/nat.2021.0043","volume":"32","author":"L Servais","year":"2022","unstructured":"Servais, L. et al. Long-term safety and efficacy data of golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1\/2 trial. Nucleic Acid Ther. 32, 29\u201339 (2022).","journal-title":"Nucleic Acid Ther."},{"key":"66765_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/ner.12693","volume":"21","author":"SJ Nagel","year":"2018","unstructured":"Nagel, S. J. et al. Intrathecal therapeutics: device design, access methods, and complication mitigation. Neuromodulation 21, 625\u2013640 (2018).","journal-title":"Neuromodulation"},{"key":"66765_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-26902-8","volume":"12","author":"M Ohyagi","year":"2021","unstructured":"Ohyagi, M. et al. DNA\/RNA heteroduplex oligonucleotide technology for regulating lymphocytes in vivo. Nat. Commun. 12, 1\u201312 (2021).","journal-title":"Nat. Commun."},{"key":"66765_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms8969","volume":"6","author":"K Nishina","year":"2015","unstructured":"Nishina, K. et al. DNA\/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat. Commun. 6, 1\u201313 (2015).","journal-title":"Nat. Commun."},{"key":"66765_CR19","doi-asserted-by":"publisher","unstructured":"Nagata, T. et al. Cholesterol-functionalized DNA\/RNA heteroduplexes cross the blood\u2013brain barrier and knock down genes in the rodent CNS. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-021-00972-x (2021).","DOI":"10.1038\/s41587-021-00972-x"},{"key":"66765_CR20","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","volume":"2","author":"F Muntoni","year":"2003","unstructured":"Muntoni, F., Torelli, S. & Ferlini, A. Dystrophin and mutations: One gene, several proteins, multiple phenotypes. Lancet Neurol. 2, 731\u2013740 (2003).","journal-title":"Lancet Neurol."},{"key":"66765_CR21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/brain\/awac048","volume":"146","author":"K Maresh","year":"2023","unstructured":"Maresh, K. et al. Startle responses in Duchenne muscular dystrophy: a novel biomarker of brain dystrophin deficiency. Brain 146, 252\u2013265 (2023).","journal-title":"Brain"},{"key":"66765_CR22","doi-asserted-by":"crossref","unstructured":"Sekiguchi, M. et al. A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice. Brain 132, 124\u2013135 (2009).","DOI":"10.1093\/brain\/awn253"},{"key":"66765_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nm1345","volume":"12","author":"J Alter","year":"2006","unstructured":"Alter, J. et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. 12, 175\u2013177 (2006).","journal-title":"Nat. Med."},{"key":"66765_CR24","doi-asserted-by":"publisher","unstructured":"Yang, L. et al. Effective exon skipping and dystrophin restoration by 2\u2032-O-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice. PLoS ONE 8, https:\/\/doi.org\/10.1371\/journal.pone.0061584 (2013).","DOI":"10.1371\/journal.pone.0061584"},{"key":"66765_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100416","volume":"296","author":"ST Crooke","year":"2021","unstructured":"Crooke, S. T., Liang, X. H., Baker, B. F. & Crooke, R. M. Antisense technology: a review. J. Biol. Chem. 296, 100416 (2021).","journal-title":"J. Biol. Chem."},{"key":"66765_CR26","doi-asserted-by":"crossref","unstructured":"Hasegawa, J. et al. Heteroduplex oligonucleotide technology boosts oligonucleotide splice switching activity of morpholino oligomers in a Duchenne muscular dystrophy mouse model. Nat. Commun. 15, 7530 (2024).","DOI":"10.1038\/s41467-024-48204-5"},{"key":"66765_CR27","doi-asserted-by":"publisher","first-page":"6029","DOI":"10.1093\/nar\/gkz354","volume":"47","author":"TP Prakash","year":"2020","unstructured":"Prakash, T. P. et al. Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle. Nucleic Acids Res. 47, 6029\u20136044 (2020).","journal-title":"Nucleic Acids Res."},{"key":"66765_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1089\/nat.2019.0794","volume":"29","author":"S Wang","year":"2019","unstructured":"Wang, S., Allen, N., Prakash, T. P., Liang, X. H. & Crooke, S. T. Lipid conjugates enhance endosomal release of antisense oligonucleotides into cells. Nucleic Acid Ther. 29, 245\u2013255 (2019).","journal-title":"Nucleic Acid Ther."},{"key":"66765_CR29","first-page":"6045","volume":"47","author":"ME \u00d8stergaard","year":"2019","unstructured":"\u00d8stergaard, M. E. et al. Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates. Nucleic Acids Res. 47, 6045\u20136058 (2019).","journal-title":"Nucleic Acids Res."},{"key":"66765_CR30","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1093\/nar\/gkaa126","volume":"48","author":"L Sheng","year":"2020","unstructured":"Sheng, L., Rigo, F., Frank Bennett, C., Krainer, A. R. & Hua, Y. Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model. Nucleic Acids Res. 48, 2853\u20132865 (2020).","journal-title":"Nucleic Acids Res."},{"key":"66765_CR31","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1038\/mt.2008.120","volume":"16","author":"N Jearawiriyapaisarn","year":"2008","unstructured":"Jearawiriyapaisarn, N. et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol. Ther. 16, 1624\u20131629 (2008).","journal-title":"Mol. Ther."},{"key":"66765_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/B978-0-12-804279-3.00004-6","volume":"146","author":"DM Barten","year":"2018","unstructured":"Barten, D. M., Cadelina, G. W. & Weed, M. R. Dosing, collection, and quality control issues in cerebrospinal fluid research using animal models. Handb. Clin. Neurol. 146, 47\u201364 (2018).","journal-title":"Handb. Clin. Neurol."},{"key":"66765_CR33","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3390\/biomedicines11051413","volume":"11","author":"MM Rahman","year":"2023","unstructured":"Rahman, M. M., Lee, J. Y., Kim, Y. H. & Park, C.-K. Epidural and intrathecal drug delivery in rats and mice for experimental research: fundamental concepts, techniques, precaution, and application. Biomedicines 11, 1413 (2023).","journal-title":"Biomedicines"},{"key":"66765_CR34","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/nar\/gkaa1235","volume":"49","author":"P Jafar-Nejad","year":"2021","unstructured":"Jafar-Nejad, P. et al. The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration. Nucleic Acids Res. 49, 657\u2013673 (2021).","journal-title":"Nucleic Acids Res."},{"key":"66765_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.neulet.2016.07.059","volume":"636","author":"B van Zundert","year":"2017","unstructured":"van Zundert, B. & Brown, R. H. Silencing strategies for therapy of SOD1-mediated ALS. Neurosci. Lett. 636, 32\u201339 (2017).","journal-title":"Neurosci. Lett."},{"key":"66765_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep21301","volume":"6","author":"M Nizzardo","year":"2016","unstructured":"Nizzardo, M. et al. Morpholino-mediated SOD1 reduction ameliorates an amyotrophic lateral sclerosis disease phenotype. Sci. Rep. 6, 1\u201313 (2016).","journal-title":"Sci. Rep."},{"key":"66765_CR37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.omtn.2022.12.010","volume":"31","author":"C Jia","year":"2023","unstructured":"Jia, C. et al. Change of intracellular calcium level causes acute neurotoxicity by antisense oligonucleotides via CSF route. Mol. Ther. Nucleic Acids 31, 182\u2013196 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"66765_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/nat.2017.0705","volume":"28","author":"LJA Toonen","year":"2018","unstructured":"Toonen, L. J. A. et al. Intracerebroventricular administration of a 2\u2032-O-methyl phosphorothioate antisense oligonucleotide results in activation of the innate immune system in mouse brain. Nucleic Acid Ther. 28, 63\u201373 (2018).","journal-title":"Nucleic Acid Ther."},{"key":"66765_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0169-328X(98)00185-5","volume":"62","author":"S Peng Ho","year":"1998","unstructured":"Peng Ho, S., Livanov, V., Zhang, W., Li, J. H. & Lesher, T. Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS. Mol. Brain Res. 62, 1\u201311 (1998).","journal-title":"Mol. Brain Res."},{"key":"66765_CR40","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1093\/nar\/gky1260","volume":"47","author":"HJ Gaus","year":"2019","unstructured":"Gaus, H. J. et al. Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay. Nucleic Acids Res. 47, 1110\u20131122 (2019).","journal-title":"Nucleic Acids Res."},{"key":"66765_CR41","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1006\/exnr.1997.6710","volume":"149","author":"GW Rebeck","year":"1998","unstructured":"Rebeck, G. W. et al. Structure and functions of human cerebrospinal fluid lipoproteins from individuals of different apoE genotypes. Exp. Neurol. 149, 175\u2013182 (1998).","journal-title":"Exp. Neurol."},{"key":"66765_CR42","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S1050-1738(00)00045-1","volume":"10","author":"G Bu","year":"2000","unstructured":"Bu, G. & Marzolo, M. P. Role of RAP in the biogenesis of lipoprotein receptors. Trends Cardiovasc. Med. 10, 148\u2013155 (2000).","journal-title":"Trends Cardiovasc. Med."},{"key":"66765_CR43","doi-asserted-by":"crossref","unstructured":"Woolf, T. M., Jennings, C. G., Rebagliati, M. & Melton, D. A. The stability, toxicity and effectiveness of unmodified and phosphorothioate antisense oligodeoxynucleotides in Xenopus oocytes and embryos. Nucleic Acids Res. 18, 1763\u20131769 (1990).","DOI":"10.1093\/nar\/18.7.1763"},{"key":"66765_CR44","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1016\/S0021-9258(18)47090-1","volume":"269","author":"DA Brown","year":"1994","unstructured":"Brown, D. A. et al. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269, 26801\u201326805 (1994).","journal-title":"J. Biol. Chem."},{"key":"66765_CR45","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","volume":"37","author":"W Shen","year":"2019","unstructured":"Shen, W. et al. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat. Biotechnol. 37, 640\u2013650 (2019).","journal-title":"Nat. Biotechnol."},{"key":"66765_CR46","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1089\/nat.2022.0005","volume":"32","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. The combination of mesyl-phosphoramidate inter-nucleotide linkages and 2\u2032-O-Methyl in selected positions in the antisense oligonucleotide enhances the performance of RNaseH1 active PS-ASOs. Nucleic Acid Ther. 32, 401\u2013411 (2022).","journal-title":"Nucleic Acid Ther."},{"key":"66765_CR47","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho, T. et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA 330, 1448\u20131458 (2023).","journal-title":"JAMA"},{"key":"66765_CR48","doi-asserted-by":"publisher","first-page":"8471","DOI":"10.1021\/acs.jmedchem.0c00840","volume":"63","author":"M Nikan","year":"2020","unstructured":"Nikan, M. et al. Targeted delivery of antisense oligonucleotides using neurotensin peptides. J. Med. Chem. 63, 8471\u20138484 (2020).","journal-title":"J. Med. Chem."},{"key":"66765_CR49","doi-asserted-by":"publisher","unstructured":"Merrill, N. J. et al. Human cerebrospinal fluid contains diverse lipoprotein subspecies enriched in proteins implicated in central nervous system health. Sci. Adv. 9, https:\/\/doi.org\/10.1126\/sciadv.adi5571 (2023).","DOI":"10.1126\/sciadv.adi5571"},{"key":"66765_CR50","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1161\/ATVBAHA.116.307023","volume":"36","author":"RW Mahley","year":"2016","unstructured":"Mahley, R. W. Central nervous system lipoproteins: ApoE and regulation of cholesterol metabolism. Arterioscler Thromb. Vasc. Biol. 36, 1305\u20131315 (2016).","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"66765_CR51","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S0022-2275(20)31605-9","volume":"42","author":"S Koch","year":"2001","unstructured":"Koch, S. et al. Characterization of four lipoprotein classes in human cerebrospinal fluid. J. Lipid Res. 42, 1143\u20131151 (2001).","journal-title":"J. Lipid Res."},{"key":"66765_CR52","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1089\/nat.2014.0528","volume":"25","author":"U Burki","year":"2015","unstructured":"Burki, U. et al. Development and application of an ultrasensitive hybridization-based ELISA method for the determination of peptide-conjugated phosphorodiamidate morpholino oligonucleotides. Nucleic Acid Ther. 25, 275\u2013284 (2015).","journal-title":"Nucleic Acid Ther."},{"key":"66765_CR53","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jmoldx.2011.08.002","volume":"14","author":"F Wang","year":"2012","unstructured":"Wang, F. et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J. Mol. Diagn. 14, 22\u201329 (2012).","journal-title":"J. Mol. Diagn."},{"key":"66765_CR54","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1038\/mt.2011.186","volume":"19","author":"H Kuwahara","year":"2011","unstructured":"Kuwahara, H. et al. Efficient in vivo delivery of siRNA into brain capillary endothelial cells along with endogenous lipoprotein. Mol. Ther. 19, 2213\u20132221 (2011).","journal-title":"Mol. Ther."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66765-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66765-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66765-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:02:01Z","timestamp":1766397721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66765-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["66765"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-66765-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"19 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.Y. collaborates with Takeda Pharmaceutical Co., Ltd. and serves as an academic advisor for Rena Therapeutics Inc. and Nissan Chemical Corporation. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10853"}}